# Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

> **NCT00425802** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 61 (actual)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** graft-versus-tumor induction therapy
- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** cyclosporine
- **DRUG:** fludarabine phosphate
- **DRUG:** mycophenolate mofetil
- **PROCEDURE:** nonmyeloablative allogeneic hematopoietic stem cell transplantation
- **RADIATION:** total-body irradiation

## Key facts

- **NCT ID:** NCT00425802
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-28
- **Primary completion:** 2016-10-28
- **Final completion:** 2016-10-28
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2017-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425802, "Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00425802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*